Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Role of laser flare photometry in predicting the risk of glaucoma in patients with pseudoexfoliation syndrome

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Glaucoma

Session Date/Time: Sunday 11/09/2016 | 15:00-16:30

Paper Time: 15:10

Venue: Poster Village: Pod 3

First Author: : S.Ben Yahia TUNISIA

Co Author(s): :    R. Kahloun   I. Ksiaa   H. Ben Amor   S. Zaouali   S. Attia   M. Khairallah

Abstract Details


To evaluate anterior chamber aqueous flare (ACAF) in Tunisian patients with pseudoexfoliation (PEX) syndrome with or without associated glaucoma.


Department of Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia


A prospective, cross-sectional, comparative study including 53 patients (88 eyes) with PEX syndrome, 48 patients with PEX glaucoma (86 eyes), and 53 healthy sex-and age-matched control subjects (106 eyes). All patients underwent a complete ophthalmic examination and laser flare photometry.


Mean ACAF was significantly higher in the PEX syndrome group in comparison with the control group (17.96 ± 10.05 vs 7.06 ± 2.95 ph/ms; p = 10-4), in patients with PEX glaucoma compared to PEX syndrome without associated glaucoma (27.99 ± 15.45 vs 17.96 ± 10.05 ph/ms; p = 10-4), in the PEX glaucoma group in comparison with control group (27.99 ± 15.45 vs 7.06 ± 2.95 ph/ms; p = 10-4), and in patients with unilateral PEX syndrome in comparison with contralateral-unaffected eyes (25.72 ± 14.88 vs 8.58 ± 3.45 ph/ms; p = 0.000).


For patients with PEX syndrome, a high ACAF might be a predictor for the development of glaucoma. Further investigations are needed to clarify the role of laser flare photometry in predicting the risk of glaucoma in patients with PEX syndrome.

Financial Disclosure:


Back to previous